SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-009666
Filing Date
2020-08-06
Accepted
2020-08-06 16:18:14
Documents
62
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20200630x10q.htm   iXBRL 10-Q 1255759
2 EX-10.1 ettx-20200630xex10d1.htm EX-10.1 15784
3 EX-10.2 ettx-20200630xex10d2.htm EX-10.2 13283
4 EX-10.3 ettx-20200630xex10d3.htm EX-10.3 9931
5 EX-31.1 ettx-20200630xex31d1.htm EX-31.1 13551
6 EX-31.2 ettx-20200630xex31d2.htm EX-31.2 12824
7 EX-32.1 ettx-20200630xex32d1.htm EX-32.1 8743
8 GRAPHIC ettx-20200630xex10d2001.jpg GRAPHIC 7536
  Complete submission text file 0001558370-20-009666.txt   5009559

Data Files

Seq Description Document Type Size
9 EX-101.SCH ettx-20200630.xsd EX-101.SCH 45041
10 EX-101.CAL ettx-20200630_cal.xml EX-101.CAL 43495
11 EX-101.DEF ettx-20200630_def.xml EX-101.DEF 147257
12 EX-101.LAB ettx-20200630_lab.xml EX-101.LAB 381062
13 EX-101.PRE ettx-20200630_pre.xml EX-101.PRE 280957
14 EXTRACTED XBRL INSTANCE DOCUMENT ettx-20200630x10q_htm.xml XML 743567
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 201081926
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences